Experiments in several laboratories have shown that vaccination with ribosome-rich extracts of species of Salmonella protects mice against subsequent experimental infection with live, virulent organisms of the same species (2, 7, 32) . These preparations have been referred to as "ribosomal vaccines." At the present time work from different laboratories has led to conflicting conclusions as to the identity of the protective substance(s), which has yet to be definitively established. Using column chromatography, Venneman (31) purified a highly protective fraction of molecular weight greater than 300,000. By chemical analysis the fraction contained no detectable protein and appeared to be entirely ribonucleic acid (RNA), although he could not completely exclude the possibility of a contaminating polysaccharide. li contrast, Johnson (7, 8) has presented evidence that points to the protein fraction as the protective moiety. Smith and Bigley (28) also found that protein fractions had protective activity, but the protein was not as active as crude ribosomal extracts.
In this laboratory, we have considered the hypothesis that the protection is due to 0 antigens contaminating the ribosomal extract. This possibility is not unlikely, since it is well known that nucleic acids and lipopolysaccharides (LPS) have a strong affinity (24) .
To investigate the contribution of 0 antigens to the observed immunity, we have used several genetically defined strains of Salmonella for preparation of ribosomal vaccines. Protection was assayed by the ability of immunized mice to suppress the multiplication of a challenge inoculum. One approach has been to use two isogenic strains. One is designated GO11, with 0 antigenic constitution 0:9,12, and the other is G024, with 0 antigens 4 and 12. Both strains are his+ transductants derived from the same S. enteritidis parent strain (T. K. Eisenstein, E. P. Ornellas, R. J. Roantree, and J. P. Steward, Bacteriol. Proc., p. 94, 1970). They are known to differ from each other only in the region of the chromosome coding for 0 antigens 4 and 9. and in the ability to ferment galactose. It is assumed, therefore, that the ribosomal RNA and ribosomal proteins are the same in both strains. Thus, vaccines prepared from either of these strains should cross-protect against the other if the ribosomal components are responsible for the protection. If, however, 0 antigens are the immunogens, then the protection should be specific for the strain from which the vaccine was prepared.
A second approach to investigating the contribution of 0 antigens to the immunogenicity of these preparations has been to test the protective capacity of vaccines prepared from mutant strains of Salmonella that have known defects in LPS synthesis.
The results presented in this paper point strongly to the conclusion that 0 antigens are Since this work was initiated, Johnson (8) has also shown that RNA fractions of ribosomes contain 0 antigens and endotoxic activity. He found that purification of the RNA with phenol and guanidine hydrochloride removed the 0 antigens, and also the protective activity. Berry et al. (2) , using gas chromatography, were able to detect 0-specific sugars in purified RNA fractions. Thus, our results and those of Johnson and Berry et al. are in agreement that 0 antigens are present in RNA-rich extracts of ribosomes which have been used as vaccines.
To date, the nature of the protective substance in the protein fraction described by Johnson (8) has not been definitively identified. Results which are presented in this paper point to the conclusion that 0 antigens also contaminate the protein fraction, and can account for its observed protective capacity. These results raise the question as to whether any of the protection resulting from immunization with "ribosomal vaccines" is due to components other than LPS.
MATERIALS AND METHODS
Mice. Outbred mice from two suppliers were used: Swiss-Webster mice from Huntingdon Farms (Conshohocken, Pa.) and CD-1 mice from Charles River Mouse Farm (Wilmington, Mass.). All (33) due to the inability to manufacture the uridine 5'-diphosphate (UDP)-galactose precursor of the galactose units of the LPS core (Fig. 1) . Its phage-sensitivity pattern is unaltered on medium supplemented with galactose, which indicates that it is unable to convert exogenous galactose to UDP-galactose, the expected result of a deletion of the whole of the gal gene cluster, including genes galK and galT, which specify enzymes needed for this conversation. Strain SL1694 is a derivative of the gal deletion mutant, TA1659, corrected of its galactose-negative character by acquisition of F'8-gal+, which includes the wild-type form of the gal gene cluster of Escherichia coli K-12. (See references 11 and 12 for restoration of smooth character, virulence, etc., of a galE mutant of S. typhimurium by introduction of an F'gal+ plasmid.) SL1102 is a rough mutant of class rfaR, making incomplete core lps of type Re, i.e., deficient in heptose (and sugars distal to it), derived from a genetically marked subline of S. typhimurium, strain LT2 (33) . Strain SL4507 is agalU mutant of a genetically marked derivative, TV253 (11) of an S. typhimurium strain of type FIRN (20) , which is deficient in UDP-glucose-pyrophosphorylase because of its inability to make the UDP-glucose, a precursor of the glucose of the LPS core. Thus, it is rough and makes LPS of type Rd (Fig. 1) . Assay of extracts for UDP-glucose-pyrophosphorylase activity suggests that its enzymic defect is incomplete (X. Kuo (34, 35) Challenge procedure. Fourteen days after immunization, mice were given an intraperitoneal challenge with live salmonella. A lyophilized vial of the desired strain was rehydrated and inoculated into a 100-ml flask of brain heart infusion broth which was grown ovemight. In the morning, 0.1 ml from this starter culture was transferred to a tube containing 10 ml of brain heart infusion broth. The culture was incubated until it reached late log phase, as determined by the OD at 640 nm in a Coleman 20 spectrophotometer (Bausch and Lomb). The organisms were then diluted to the desired concentration in saline. The cultures were kept on ice between standardization and injecabe* gic Assay for protection. Five days after infection, mice were killed, and the total number of bacteria in each carcass was determined by the method of Berry (1) . The skin and digestive tract were removed, and the carcass was homogenized in sterile, distilled water in a Waring Blendor (model 5010) for 3 min. Appropriate dilutions were plated on eosin-methylene blue agar plus 1% galactose as described above. By plating 0.1 ml of the undilutedshomogenate, the smallest number of organisms detectable was 1,000. To distinguish the infecting strains from coliform contaminants, slide agglutinations, using typing sera (Lederle Diagnostics), were performed on questionable colonies. A record of the mortality in each group was also kept in most experiments for the 5-day period between infection and sacrifice to provide additional data about protection. Dying mice usually have greater than 1 x 10' organisms in their carcasses (1).
Assessment of specificity of protection. To quantitate the relative growth of the G024-(0:4) and GO11+ (0:9) strains in double-challenge experiments, a specificity ratio (SR) was defined as the ratio of galh (0:4,12)/gal+(0:9,12) organisms in the carcass. An average SR for each group of mice was determined.
Passive hemagglutination. To raise antisera. groups of 50 mice were injected i.p. three times at 7-day intervals. Each time, they received either 1 OD2,0 unit of Y-RNA vaccine prepared from G024-or GO11+, or 50 Ag of LPS of S. enteritidis or S. typhimurium (Difco). Control serum was collected from animals similarly injected with water. One week after the last injection the animals were anesthetized with chloroform and bled out from the heart. Pooled sera were filtered, first through an 0.45-Am membrane filter (Millex; Millipore Corp.) and then through a 0.22-gm filter and stored at -20 C in small aliquots.
To test the antibody titers to 0 antigens induced by the vaccine, human group 0 erythrocytes were coated with LPS (Difco) of S. enteritidis (0:9,12) or S. typhimurium (0:1,4,5,12) using the method of Neter (22) as described by Nowotny (23) . The LPS (2 mg/ml) was boiled for 2 h. One part of packed erythrocytes was added to five parts of LPS and incubated for 1 h at 37 C. The sensitized cells were washed three times with saline and diluted to a final concentration of 1% with saline. Dilutions of the sera were then made in microtiter plates with tapered walls (Microbiological Associates). Typing sera (Lederle Diagnostics) were used as the positive control, and appropriate controls using uncoated cells were always included. Serum (0.025 ml) was Table 5 ). It is interesting that both the 9,12 and 4,5,12 LPS induced substantial specific antibody, and little cross-reactive antibody, in spite of the 12 antigen in common. The sera raised against the 9,12 ribosomal vaccine is also specific for 9, 12 LPS as shown by the failure of 4,5,12 LPS-coated cells to absorb out the antibody. In contrast, the anti-4,12 ribosomal serum shows low titers against the homologous LPS and significant cross-reactivity against the heterologous LPS. Furthermore, the titer to the homologous and heterologous LPS is absorbed out by the heterologous 9,12 LPS. Thus the antibody studies confirm that 0 antigens are present in the ribosomal preparations, but there is no correlation between the pattern of specificity in the antibody response and the specificity of protection induced by the vaccine. Heat resistance of ribosomal vaccines. The preceding double-challenge experiments indicated that there were two immunogens in the G024-Y-RNA vaccine, one that was specific, presumably the 0:4 antigen, and one that was cross-protective. The cross-protective antigen could be 0:12 or it could be some other antigen which the isogenic strains have in common, in their cell walls or in their ribosomes. One of the distinguishing features of LPS is its heat stability (10) . Accordingly, the effect of heat on the protective capacity of the G024-(0:4,12) vaccine was examined. Boiling for 30 min did not alter the homologous or the heterologous protective capacity of the preparation (Table 6) . A similar experiment was performed on S. adelaide ribosomal vaccine. As shown in Table  7 , boiling had no effect on the level of protection it induced.
Protection by ribosomal fractions prepared by the method of Fogel and Sypherd. In the experiment shown in Table 8 , mice were immunized with 3.0 OD260 units of FS-RNA prepared from G011+ (0:9,12) or G024+ (0:4,12) . It is evident that the G024-and G011+ vaccines induced greater specific protection against the homologous isogenic strain than against the heterologous one, in a manner similar to that seen with Y-RNA vaccines (see Table 3 ). A comparison of the average SR of saline-injected animals and of mice vaccinated with the G024-vaccine shows that there was a 15-fold decrease in the ratio in the vaccinated animals. Similarly, mice vaccinated with the G011+ vaccine had a 39-fold increase in SR as compared with controls. These results show that ribosomal RNA extracts prepared from the isogenic strains by two different methods yield similar data. Table 9 shows the results of an experiment in which a second batch of ribosomes was prepared 'Typing sera specificity.
of the ribosome fraction with 2-chloroethanol. A comparison of these results with those in Table  8 shows that the FS-RNA fraction, at a dose of 1 OD2,0 unit, gives similar results to those obtained with this vaccine at 3.0 OD2*0 units (Table 8 ). The overall level of protection is slightly lower, but the specific protection indices are about the same as seen with the higher dose. A new and important observation is that the protein fraction, like the RNA fractions, results in highly significant specificity of protection, in addition to some nonspecific protection. DISCUSSION Mice immunized with salmonella ribosomes, or ribosomal subfractions, show high levels of immunity to subsequent challenge with living salmonellae. The present studies have tested the hypothesis that the protective activity of these fractions is due to 0 antigens which contaminate these preparations.
With regard to the RNA-rich fractions, four lines of evidence support the conclusion that 0 antigens are present in the vaccine and are responsible for at least part of their observed protective capacity. (i) A vaccine prepared from a deletion mutant which lacks 0 antigen does not protect, but a vaccine prepared from its smooth derivative gives excellent protection; (ii) the protection afforded by vaccines prepared from isogenic strains shows specificity; (iii) 0 antibodies are present in antisera raised to RNA-rich vaccines; and (iv) the immunogenicity of the vaccines is not affected by boiling for 30 min, a finding which is consistent with the well-known heat stability of 0 antigens.
With regard to the protein extract of the ribosomes, the evidence from the experiments using isogenic strains suggests that 0 antigens are also present in this fraction and account for at least part of its protective capacity.
The use of the isogenic strains in conjunction with the double-challenge technique has been extremely useful in providing insight into the nature of the vaccine immunogen. We have found that RNA and protein "ribosomal" fractions induce a strain-specific protection. Since these strains are isogenic, and are expected to be identical except for their 0 antigens, at least part of the protective activity of these fractions must be attributed to contamination with 0 antigens. The only other explanation for the observed specificity would be that these two strains differ also in their ribosomal RNAs or proteins. Although no rigorous proof is available for the assumption that the ribosomal RNA and VOL. 12, 1975 on October 16, 2017 by guest http://iai.asm.org/ proteins in the two strains are the same, it is known that no more than 1% of the chromosome is transferred during transduction, which in this case was confined to the loci which code for his and the 0 antigens. These loci map at 65 min on the salmonella chromosome (27) . The genes coding for ribosomal RNAs and protein that have been mapped are located far enough from this region to make it unlikely that they were directly affected by the transduction (25, 27) . With regard to the vaccines prepared from strains of Salmonella with deficiencies in lipopolysaccharide synthesis, the degree of protection they induce seems to correlate with their degree of "leakiness" rather than with the depth could account for the protection induced by its ribosomal extract. Strain SL1102 tends to accumulate smooth revertants (Stocker, personal communication) , and may be slightly leaky (29) . This might account for the moderate protective capacity of the ribosomal vaccine prepared from it. The results and conclusions presented here concerning 0 antigens in the RNA-rich ribosomal fractions are in agreement with those of other investigators (2, 7). However, our interpretation of the species-specific protection of the protein fraction as being due to the presence of 0 antigens is not the interpretation of other laboratories. Johnson has suggested that unique ribosomal proteins are responsible for the immunogenicity and species specificity of this fraction (8 (9, 30) , whereas the serological specificity is associated with the 0 sugars (see Fig. 1 ). It is possible that haptenic 0 antigenic groups sucn as those termed native hapten" (26) , which show no endotoxic activity but are still immunogenic, can complex with the ribosomal proteins in the extraction process.
In addition to the specific protection induced by the ribosomal vaccines, double-challenge experiments with the isogenic strains revealed significant cross-protection. The antibody studies indicate that at least part of this cross-protection could be due to the humoral response to the 12 antigen which the two strains have in common. However, the experiments using S. adelaide ribosomal vaccines show that in addition to the 0 antigens, there is another immunogenic determinant in these preparations which induces a protective response. (17, 18, 39) . Anti-lipid A antibodies have been shown to enhance blood clearance of Salmonella (16) . An as yet unidentified cross-protective antigen present in lipid A extracts of rough strains of Salmonella has been described (21) . It is possible that in the procedure for extraction of the ribosomal RNA, incomplete, rough LPS chains complex with the ribosome and are rendered immunogenic. Alternatively, the antigen in the S. adelaide vaccine might be Kunin's common antigen (13) , which VOL. 12, 1975 on October 16, 2017 by guest http://iai.asm.org/ Downloaded from 376 EISENSTEIN has been shown to induce some cross-protection against salmonella challenge (4). The possibility must also be considered that the cross-protective effects are due to either protein or RNA which is acting as a common antigen. However, the observation that the Y-RNA extracted from the Rc mutant, TA1659, did not protect makes it unlikely that RNA functions as a cross-protective immunogen. Experiments to evaluate the contribution of the protein to cross-protection are in progress.
In light of the evidence presented in this paper, that 0 antigens can contaminate ribosomal preparations, one might raise the question as to whether the ribosomes make any contribution to the observed protection. In this regard it should be noted that the immunogenicity of whole Salmonella ribosomes is not reduced by treatment with RNase, Pronase, or trypsin (32) . Furthermore, in the case of another gram-negative organism, Vibrio cholerae, Jensen et al. (6) have shown that the protective antigen in ribosomal preparations can be separated from the ribosomes. The antigen is a colloid of cell wall origin which contains protein, lipid, and carbohydrate. It does not need to be complexed with the ribosomes to be protective, although a comparison of protective capacity on a weight basis between complexed and noncomplexed antigen was not reported.
If the ribosomes do serve a function it seems most reasonable that they have an adjuvant role and serve as carriers for 0 antigens or other wall or membrane antigens. In the case of the Salmonella, there is some evidence that ribosomal preparations are more protective on a weight basis than LPS given alone (32) . However, a systematic appraisal of the relative efficacy of LPS, ribosome-associated LPS, and LPS complexed with ribosomal fractions has not been reported, and would help to elucidate the contribution of the ribosomal components, if any, to the immunity induced by these preparations.
